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A targeted next-generation 
sequencing method for identifying 
clinically relevant mutation profiles 
in lung adenocarcinoma
Di Shao1,2,3,*, Yongping Lin4,5,6,*, Jilong Liu1, Liang Wan1, Zu Liu1, Shaomin Cheng1, 
Lingna Fei1, Rongqing Deng1, Jian Wang1, Xi Chen1, Liping Liu6, Xia Gu6, Wenhua Liang6, 
Ping He6, Jun Wang2, Mingzhi Ye1,2,3 & Jianxing He6
Molecular profiling of lung cancer has become essential for prediction of an individual’s response to 
targeted therapies. Next-generation sequencing (NGS) is a promising technique for routine diagnostics, 
but has not been sufficiently evaluated in terms of feasibility, reliability, cost and capacity with routine 
diagnostic formalin-fixed, paraffin-embedded (FFPE) materials. Here, we report the validation and 
application of a test based on Ion Proton technology for the rapid characterisation of single nucleotide 
variations (SNVs), short insertions and deletions (InDels), copy number variations (CNVs), and gene 
rearrangements in 145 genes with FFPE clinical specimens. The validation study, using 61 previously 
profiled clinical tumour samples, showed a concordance rate of 100% between results obtained by NGS 
and conventional test platforms. Analysis of tumour cell lines indicated reliable mutation detection in 
samples with 5% tumour content. Furthermore, application of the panel to 58 clinical cases, identified 
at least one actionable mutation in 43 cases, 1.4 times the number of actionable alterations detected by 
current diagnostic tests. We demonstrated that targeted NGS is a cost-effective and rapid platform to 
detect multiple mutations simultaneously in various genes with high reproducibility and sensitivity.
Lung cancer is the most common cancer and the leading cause of cancer death in China, accounting for 1/5 of 
total cancer incidence and 1/4 of all cancer-related mortality1. The incidence rate of lung cancer in China has 
been increasing during the past several decades at a more rapid rate than in western countries1. The treatment 
of non-small cell lung cancer (NSCLC) with platinum-based chemotherapy has reached a plateau of effective-
ness. Personalised therapy which targets tumour-specific molecular abnormalities is gradually starting to play 
an important role in the systemic treatment plan for cancer patients2. In lung adenocarcinoma, multiple genetic 
alterations have already been identified as therapeutic targets, including mutations of the EGFR gene and rear-
rangements of the ALK and ROS1 genes. Drugs designed specifically as inhibitors of these molecular targets have 
significantly extended the survival times for patients whose tumours harbour these mutations3–6. In addition, 
several other target oncogenes with potential prognostic role in lung adenocarcinoma, including MET, PIK3CA, 
and RET, have also been described, and target agents are currently under evaluation7.
Given the increased availability of various targeted therapies, comprehensive characterisation of mutations in 
clinically actionable genes and key cancer pathways have become necessary to improve our understanding of the 
genetic basis of the disease, to choose suitable treatment options, and to aid in the estimation of prognosis and 
drug resistance8,9. However, this has also brought a great challenge to routine pathology, as approximately 64% 
of lung adenocarcinomas harbour at least one somatic oncogenic mutations in EGFR, HER2, KRAS, PIK3CA, 
BRAF, MEK1, and ALK10,11. In current clinical practice, tumor molecular profiling involves multiple assessments 
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(Amplification Refractory Mutation System PCR, Sanger sequencing, fluorescence in situ hybridisation, and 
immunohistochemistry), each of which targets a single gene or type of mutation, resulting in increased costs 
and turnaround time. In addition, when mutational assessment of multiple genes is needed, traditional methods 
require a large quantity of DNA, which is often difficult to obtain in clinical settings12.
Massively parallel or next-generation sequencing technology is increasingly being used for mutational analysis 
of tumours for both clinical and research applications13–15. Targeted next-generation sequencing of cancer-related 
genes allows rapid detection of a variety of somatic mutations on single platforms (such as Ion Proton and 
MiSeq)16–18. Although, many studies have demonstrated the feasibility of this method, there are several problems 
to overcome before it can be applied to routine diagnostics in the clinic19–21. Firstly, in routine diagnostics, the 
majority of cancer specimens are formalin-fixed, paraffin-embedded (FFPE) samples, which yield DNA in limited 
quantity due to degradation and cross-linking. Therefore, optimised sequencing library preparation for fragment 
DNA input is required. Secondly, an efficient and robust algorithm is needed to detect all types of cancer muta-
tions, including SNVs, InDels, CNVs, and gene rearrangements. Finally, the NGS method should be comparable 
with current conventional test in all aspects, including turnaround time, sensitivity, specificity, mutation detec-
tion limits, costs, and capacity.
To evaluate the feasibility of applying an NGS technique to mutation analysis of routinely obtained specimens 
in a clinical molecular diagnostic laboratory, we developed a targeted NGS test designed to detect 436 exons 
in 145 genes relevant to personalised therapy in lung cancer. Next, we validated the method in retrospective 
FFPE-DNA samples and cancer cell lines by comparing the results with those obtained by conventional methods. 
Finally, we assessed the performance of the validated test in routine pathology practice.
Results
Description of workflow. We developed and optimised a targeted next-generation sequencing technical 
platform to detect actionable and clinically relevant mutations in clinical routine specimens. An overview of the 
test is shown in Fig. 1, the entire workflow lasts approximately six days. In brief, following a quality assessment of 
FFPE samples by a pathologist, quantified DNA was used to prepare the NGS sequencing library, during which 
a six-base pair DNA barcode was ligated to the ends of DNA fragments, allowing multiple samples to be pooled 
before hybrid selection. These DNA libraries were subjected to solution-phase hybrid capture with biotinylated 
RNA baits targeting 436 exons from 145 cancer related genes. After a quality control (QC) step, three captured 
libraries were pooled and sequenced by the Ion Proton instrument. An average sequencing output of 13.48 gigab-
ases (Gb) was generated for each run. SNVs, InDels, CNVs and gene arrangements were detected by a customised 
analysis pipeline. Finally, the test report was automatically generated based on the drug and mutation database.
Hybridisation chip design and capture performance. To reduce genome complexity prior to sequenc-
ing, we designed a panel of 145 clinically related genes in lung cancer. These genes were divided into two main 
parts (Supplementary Table 1). Part I genes harbour mutations that are clinically actionable now or in the future; 
these include targets of existing targeted therapies in the National Comprehensive Cancer Network (NCCN) 
guidelines and targets under active development in clinical trials. Part II genes include prognostic markers, 
and other oncogenes and tumour suppressors that are frequently mutated in cancer according to the Catalogue 
of Somatic Mutations in Cancer (COSMIC), The Cancer Genome Atlas (TCGA) or the International Cancer 
Genome Consortium (ICGC). Altogether, these genes comprised 436 exons encoding 249 kilobases. We then 
designed and synthesised 88,102 unique biotinylated RNA baits corresponding to these genomic regions.
Initially, we established our approach using genomic DNA from cell lines with known mutations. Due to the 
poor quality of FFPE DNA, we then optimised library preparation and hybridisation methods using archival 
FFPE samples. In the final protocol, four to six libraries were subjected to a single hybrid reaction, with up to 20 
barcoded libraries pooled for sequencing in a single Ion Proton run. This produced 13 Gb of raw data, which cor-
responds to approximately 6.9 million reads per sample. After marking duplicates and filtering low quality reads, 
an average of 4.7 million clean reads were generated per sample. The percent of effective bases on target averaged 
32.99%, the average depth of the target exceeded 450-fold, and more than 96.26% bases had at least 20-flod cov-
erage, indicating the suitability of this method for identifying mutations (Figure S1).
Mutation detection limit and reproducibility assessed by cell lines. We designed an analysis pro-
gram with the theoretical aim of reaching the level of sensitivity and specificity beyond 99% for mutant allelic 
frequency > 0.03. Performance was verified to be reliable by the following procedure. We mixed positive cell 
lines that harboured actionable mutations, whose allelic frequency was considered as 50%, with DNA from the 
YH cell line, to make up virtual tumour samples harbouring gradients of hierarchical allelic frequency, i.e. 1%, 
3%, 5%, 10%, successively. For SNVs, we detected all six mutations with an allelic frequency down to 3%, and 4/8 
(50%) mutations with only 1% allelic frequency. Regarding InDels, all mutations including those with an allelic 
frequency of 1%, were detected (Table 1). The measured value of the detection limit in the serial dilution studies 
was in accordance with the theoretical value. Intra-run reproducibility was tested with three samples harbouring 
three mutations across two genes. Eight replicate libraries with different barcodes from each sample were pooled 
for hybridisation and sequencing in an Ion Proton run. All the mutations were detected reproducibly, and the 
depth of aligned reads and detected variant read frequency were highly reproducible (Table 2).
Sequencing of archival samples with known mutations. We then evaluated the performance of 
targeted NGS in a clinical setting using FFPE tissue from 61 patients with lung adenocarcinoma. All samples 
underwent successful targeted sequencing of the 145 genes. We compared the gene mutation results of targeted 
NGS with the results (including mutations in EGFR, KRAS, BRAF, PIK3CA, ALK, and ROS1) obtained from a 
variety of current clinical technologies, including amplification refractory mutation system PCR (ARMS-PCR), 
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Figure 1. Workflow and turnaround time for molecular profiling of clinical samples using targeted NGS. 
Abbreviations: QC, Quality Control; FFPE, Formalin-Fixed, Paraffin-Embedded; TAT, turnaround time; NGS, 
next-generation sequencing.
Mutation Type
Mutation 
Frequency No. of Samples
Detected by 
NGS
SNV EGFR T790M
1% 4 3
3% 3 3
5% 8 8
10% 3 3
SNV EGFR L858R
1% 4 3
3% 3 3
5% 8 8
10% 3 3
InDel EGFR c.2235_2249del15
1% 4 4
3% 3 3
5% 8 8
10% 3 3
Table 1.  Detection limit of the targeted NGS method.
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Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). A concordance rate of 100% 
between the results of conventional platforms and NGS were archival (Table 3). All mutations detected by the 
conventional methods were detected by targeted NGS. Several mutations were detected in samples contain-
ing only 10–15% tumour cells, in which the CT value of ARMS-PCR was close to the cut-off value (Table S2). 
Moreover, additional four mutations in these six genes were identified because of the high sensitivity of targeted 
NGS. In some cases, a major driver mutation coexisted with other variants, as in the case of #A21, which showed a 
deletion mutation in EGFR EX19 in 17.54% of mutant alleles as well as lower frequency H1047L mutation (8.87%) 
in PIK3CA (Table S2). Furthermore, our pipeline found additional actionable mutations as a result of the broader 
target range compared with the traditional methods (Figure S2).
Data interpretation and reporting. To aid accurate interpretation of the data from the assay and the sub-
sequent communication of that information to clinicians, we developed an automatic process for data interpre-
tation and reporting. By aggregating information from publicly available resources such as My Cancer Genome, 
the Gene-Drug Knowledge Database, the NCCN guidelines, primary literature, and expert opinion, we first gen-
erated a database of tumour alterations relevant for personalised lung cancer therapy. The database integrated 
115 variants, including 49 SNVs, 45 InDels, 19 fusions and 2 amplifications in 15 genes with 27 targeted drugs. 
Following the analysis and annotation, a final list of the variants was produced, and the clinical action associated 
with each variant, and the negative genes for which no mutations were detected. According to an internally estab-
lished classification scheme, evidence of potential drug efficacy or resistance in lung cancer patients carrying the 
somatic variants were classified into two categories and with four to five levels, as summarised in Table 4.
Detection of clinically actionable alterations in patients. Having demonstrated that the targeted 
NGS test displayed sufficient to detect multiple mutations with high reproducibility and sensitivity, we further 
sought to assess the value of practical application of the test in a clinical setting. A total of 58 patients diagnosed 
with lung adenocarcinoma were included in a prospective study from January 2015 to May 2015. Of the samples 
for which sequencing was possible, 62% of the samples contained a level 1 variant, twelve percent of the samples 
had a level 2 variant. By this measure, at least one potentially actionable variant (level 1 or 2) was identified in 
74% of the samples that could be sequenced, 1.4 times the number of actionable alterations detected by current 
diagnostic tests. Figure 2 shows the frequencies of genetic alterations in patients with lung adenocarcinoma. The 
genetic alterations included: an EGFR mutation in twenty two (46%) patients; a KRAS mutation in eleven (23%); 
a PIK3CA mutation in six (12%); a BRAF mutation in three (6%); an ALK-EML4 fusion in two (4%); a MET copy 
number gain in one (2%); a PTEN mutation in one (2%); an AKT mutation in one (2%) and an FGFR1 copy num-
ber gain in one (2%). Of the 22 patients with EGFR mutations, 11 contained the L858R point mutation in exon 21, 
and 10 had deletions in exon 19. There was high concordance between the NGS platform and conventional meth-
ods; of the 38 mutations identified by ARMS-PCR or FISH, 36 mutations were also called by NGS. Furthermore, 
using the targeted NGS platform, additional mutations in other genes were identified in these 58 tumour samples 
as shown in Figure S2.
Mutation
barcode samples
mean SE
Sensitivity 
(%)1 2 3 4 5 6 7 8
Variant frequency (%)
EGFR L858R 7.50% 7.30% 5.30% 7.00% 5.70% 8.80% 11.50% 5.80% 7.36% 0.019 100%
EGFR T790M 6.70% 4.90% 7.80% 7.50% 7.00% 11.30% 9.50% 11.90% 8.33% 0.022 100%
EGFR EX19 Del 5.61% 6.04% 8.57% 8.11% 8.03% 7.96% 8.36% 5.36% 7.25% 0.013 100%
Coverage(x)
EGFR L858R 313 262 334 91 260 443 304 330 292.13 92.816
EGFR T790M 254 178 271 91 213 333 233 226 224.88 66.139
EGFR EX19 Del 410 530 992 814 872 754 825 784 747.63 176.173
Table 2.  Intra-run reproducibility.
Mutation Type Gene Platforms Expected Detected % Concordance
SNV EGFR ARMS-PCR 22 22 100%
SNV KRAS ARMS-PCR 16 16 100%
SNV PIK3CA ARMS-PCR 2 2 100%
Deletion EGFR ARMS-PCR 16 16 100%
Insertion EGFR ARMS-PCR 1 1 100%
Gene Fusion ROS1 FISH 2 2 100%
Gene Fusion ALK FISH 1 1 100%
Gene Fusion RET FISH 1 1 100%
Total – – 61 61 100%
Table 3.  Concordance of targeted NGS with conventional platforms.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:22338 | DOI: 10.1038/srep22338
Discussion
Multiple genetic alterations have already been identified as therapeutic targets for lung adenocarcinoma. 
Comprehensive characterisation of mutations in clinically actionable genes and key cancer pathways can be help-
ful for prognostic prediction and guiding the selection of therapy, ultimately accelerating the development of per-
sonalised treatment2. To this end, we established an NGS mutation assay for the detection of actionable mutations 
in routine FFPE samples of lung adenocarcinoma which we have comprehensively demonstrated to perform to a 
high clinical standard. In this study, we sequenced 145 cancer related genes from 119 FFPE tumour DNA samples. 
Benefiting from the optimisation of library preparation for FFPE DNA, we archival 480-fold mean coverage per 
sample. The uniformly high sequence coverage across all test regions afforded robust, simultaneous detection of 
SNVs, InDels, amplifications, and gene rearrangements (Fig. 3). The overall performance of our test was high. In 
cell line models, the mutation detection limit was 5% for base substitutions, and 1% for InDels. Compared to cur-
rent clinical tests, the concordance on mutually tested markers exceeded 95% for all alteration types. In contrast to 
the commercial multiple PCR panels such as Ion Ampliseq (Life technologies, Carlsbad, CA) which cannot detect 
gene rearrangement in FFPE DNA, our approach permits the detection of clinically relevant gene rearrangements 
such as those involving in ALK, ROS1, RET, and PDGFRA.
In recent years, an increasing number of publications have reported both the potential and the limitations 
of the NGS application in cancer detection and diagnosis22. However, before NGS technologies can be applied 
to routine pathology molecular diagnostics, more studies are needed to ensure consistent and reliable perfor-
mance. Most importantly, comparisons with current conventional tests in all aspects, such as turnaround time, 
sensitivity, specificity, mutation detection limits, costs, and capacity are required. In the present study, we sys-
tematically investigated the feasibility and reliability of an NGS platform for use in a routine setting using a 
combination of cell lines and 119 clinical samples. It is crucial to ensure the quality of the result when it may be 
Pattern Level Evidence
Sensitivity to 
targeted drugs
1A Drug is FDA-approved for lung cancers harbouring the variant.
1B Drug is clinically effective in the biomarker-selected cohort of lung cancer. The variant, which has a definite function feature, belongs to the cohort.
2A Drug is FDA-approved for another tumour type harbouring the variant. Clinical trials have proved its effectiveness in lung cancer patients with the variant.
2B Drug is FDA-approved for another tumour type harbouring the variant. Case reports have indicated its effectiveness in lung cancer patients with the variant.
2C Drug is FDA-approved for another tumour type harbouring the variant. Pre-clinical research has indicated its effectiveness in lung cancer patients with the variant.
Resistance to 
targeted drugs
1A NCCN guideline has clearly indicated that the variant is associated with resistance to the FDA-approved lung cancer drug.
1B
NCCN guideline has indicated drug resistance to the biomarker-selected cohort 
of lung cancer. The variant, which has a definite function feature, belongs to the 
cohort.
2A Case reports have indicated drug resistance in the lung cancer patients with the variant.
2B Pre-clinical research has indicated drug resistance in lung cancer patients with the variant.
Table 4.  Variant classification scheme.
Figure 2. Relative proportions of genomic aberrations in lung adenocarcinoma (N = 58). (A) Actionable 
variants and gene frequencies detected in 58 prospective samples. (B) Distribution of the patients according to 
the classification of detected actionable mutations.
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used to guide treatment decisions. The NGS method detected all expected variations (n = 61) in samples with 
conditional golden methods (ARMS-PCR/FISH). The NGS platform also detected mutations that are not assayed 
by genotyping or allele-specific PCR-based mutation profiling platforms. Thus, NGS can detect a broader range 
of genomic alterations than current clinical assays which may uncover more actionable options for patients. The 
experimental sensitivity of our assay was estimated to be 1% and 5% for SNVs and InDels respectively, which is 
higher than that of routine molecular methods. Several actionable somatic alterations were detected in samples 
with tumour purity as low as 10–20%, which is not achievable by conventional methods (Table S2). This high 
sensitivity is especially important for the study of EGFR T790M heterogeneity, because quantitative assessment by 
targeted NGS could enable early predication of acquired resistance to tyrosine-kinase inhibitors (TKIs) as shown 
in case #A44(Table S2).
Turnaround time (TAT) and cost are key issues for the transfer of NGS technology to routine molecular diag-
nostics. The overall cost, including chemicals, labour, and depreciation expenses for our target NGS approach was 
$198 per sample, whereas the cost of Sanger sequencing for 15 genes in our lab was $647 per sample. Although the 
price of a total NGS run is relatively high, hybridisation based DNA enrichment and DNA barcoding decreases 
the sequencing cost per sample greatly. Benefiting from the fast sequencing of the Ion Proton instrument and the 
automatic analysis and report software, the turnaround time for the entire assay from specimen acquisition to 
clinical reporting is only six days, faster than the Illumina Hiseq platform (an average of five weeks) and slightly 
slower than the Sanger sequencing (three days)23.
In conclusion, our study proves the feasibility of targeted NGS for profiling of actionable genetic alterations in 
FFPE tumour samples. Compared with conventional gene-specific assays NGS showed great advantages in terms 
of higher sensitivity, lower costs per sample, a broader range of detectable mutations, and we therefore believe that 
NGS technologies will likely to become routine for clinical tumour sample testing in the future.
Methods
Tumour tissue and cell lines. This study was approved by the Institutional Review Board of Beijing 
Genomics Institution (BGI) and was carried out in accordance with the approved guidelines. Before the surgery, 
all the patients were informed about the purpose of the study and agreed by signing an informed consent. Human 
male genomic DNA from the YH24 cell line was used as a wild-type control. We studied 119 formalin fixed, par-
affin-embedded tumour specimens from lung adenocarcinoma patients treated at The First Affiliated Hospital 
of Guangzhou Medical University (Table 5 and Table 6). All selected patients had a clinical indication for EGFR 
mutation testing. Tumour cell proportion of the specimens, reviewed by a pathologist, ranged from 10% to over 
80%. Cell line genomic DNA was purchased from the American Type Culture Collection (ATCC). Confirmation 
of cell line genomic DNA was performed by allele-specific PCR and Sanger sequencing. Mutations detected by 
NGS that were not covered by the ARMS-PCR and FISH assay were confirmed by Sanger sequencing.
Figure 3. Gene fusion and CNV detected in archival samples. (A)ALK-EML4 fusion found in sample #A59. 
ALK and EML4 break at chr2 29446561 and chr2 42523152, respectively. Then the minus stand of EML4 was 
reverse conjoined to ALK. (B) Confirmation of ALK-EML4 fusion by FISH. (C) MET amplification found in 
sample #P46. Gene region from 116435940 to 116436719 on chromosome 7 had a copy number of three.  
(D) Confirmation of MET amplification by immunohistochemistry.
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DNA extraction. DNA was extracted from unstrained FFPE resections using the QIAamp DNA FFPE Tissue 
Kit. Xylene was added twice or more to each sample as requred for paraffin removal. Ethanol (100%) was added 
once for xylene removal. Samples were resuspended in Buffer ATL and proteinase K for tissue lysis at 50 °C with 
800-rpm shaking until tissue were completely lysed. After 1h of 90 °C incubation, buffer AL and 100% ethanol 
was added for further cell lysis and DNA precipitation. DNA was eluted in 750–100 μl of Buffer ATE. The concen-
tration of DNA was measured using a Qubit fluorometer (Life Technologies, Thermo Fisher). Agarose gel (2%) 
electrophoresis was performed for quality control.
Selection of targeted genes. The chip was designed and synthesised domestically and began with includ-
ing whole exons of potential driver genes related to lung cancer literarily. We then expanded it with exons con-
taining recurrent mutations based on the Catalogue of Somatic Mutations in Cancer (COSMIC), The Cancer 
Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) to maximise the number of 
patients covered and the number of missense mutations per patients. Finally, introns and exons spanning recur-
rent fusion breakpoints of ALK, ROS1, RET, and PDGFRA were also included. Collectively, the chip targets 436 
exons, 13 introns from 145 tumour related genes, in a total size of 249 kb and covers 55,984 patients’ samples from 
the COSMIC database.
Hybrid selection and sequencing. Isolated FFPE DNA (200–500 ng) was fragmented prior to library 
construction using the Bioruptor Pico sonicator (Diagenode). After end-repairing and ligating to barcode adapt-
ers, ligated fragments were amplified for 12 cycles using Phusion High-Fidelity DNA Polymerase (Finnzymes, 
Thermo Fisher). Double-step size selection using Agencourt Ampure XP beads (Beckman-Coulter) was per-
formed by adding 0.9× and 0.15× of beads to obtain fragments between 230–270 bp in length. Indexed libraries 
were then subjected to self-synthesised custom capture probe hybridisation. Four to six indexed libraries were 
pooled in a single capture hybridization at 65 °C for 24 h. After stringent washing, captured fragments were ampli-
fied for 10 cycles using Phusion High-Fidelity DNA Polymerase. Quality and quantity were measured using the 
Qubit fluorometer and Agilent 2100 Bioanalyzer (Agilent). Multiplexed libraries were pooled proportionally and 
sequenced using an Ion Proton Sequencer (Life Technologies, Thermo Fisher).
Mutation detection and reporting. We developed a bioinformatics pipeline for processing the sequenc-
ing data named Otype in which SNVs, InDels, CNVs, and gene rearrangements are simultaneously detected with 
high sensitivity and specificity (Fig. 1). Raw data from Torrent Suite were processed with standard steps, which 
included trimming bases of low quality, alignment of reads to a reference genome hg19, and marking of dupli-
cate reads, to get standard bam files. SNV and InDel are treated simultaneously and equally. For actionable and 
druggable mutations, we have archival a program which is capable of reaching sensitivity and specificity beyond 
99% for mutant allelic frequencies > 0.03 (supplemental materials) with Q30 reads. CNVs were detected using 
CONTRA, and gene arrangement is detected by SeekSV. Without a matched normal, interpretation focused on 
Characteristic N = 61 %
Gender
 Male 26 42.6
 Female 35 57.4
Age
 Average 63.9 –
 Range 41–88 –
Smoker
 Never 40 65.6
 Light (pack-year < 30) 8 13.1
 Heavy (pack-year > 30) 13 21.3
Grade
 G1 11 18.0
 G2 44 72.1
 G3 6 9.8
Stage
 I 13 21.3
 II 21 34.4
 III 19 31.1
 V 8 13.1
Tumour content
 10%–30% 31 50.8
 30%–70% 28 45.9
 > 70% 2 3.3
Table 5.  Demographic and histopathological features of the archived samples.
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known somatic hotspot mutations, including SNVs, InDels, as well as known CNVs and gene arrangements in 
lung cancer. The mutations were annotated according to databases of established and experimental therapies to 
identify potential clinical actionability and predisposing alterations. Finally, reporting was focused on alterations 
associated with clinically available targeted treatment options.
Confirmation of mutations by Sanger sequencing. We selected samples with novel mutations from 
targeted NGS for validation testing by allele-specific PCR and Sanger sequencing. Samples with inconsistent 
analysis result between targeted NGS and ARRMS/FISH were verified by Sanger sequencing. Sanger sequencing 
was performed using the BigDye Terminator Version v3.1 Cycle-sequencing Kit (Applied Biosystems) and an ABI 
3730xl DNA sequencer (Applied Biosystems).
References
1. Chen, W., Zheng, R., Zeng, H. & Zhang, S. Epidemiology of lung cancer in China. Thorac Cancer 6, 209–215 (2015).
2. Dienstmann, R., Rodon, J., Barretina, J. & Tabernero, J. Genomic Medicine Frontier in Human Solid Tumors: Prospects and 
Challenges. J Clin Oncol 31, 1874–1884 (2013).
3. Aisner, D. & Marshall, C. Molecular Pathology of Non–Small Cell Lung Cancer. Am J Clin Pathol 138, 332–346 (2012).
4. Maemondo, M. et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 362, 
2380–2388 (2010).
5. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-
cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12, 735–742 
(2011).
6. Solomon, B. et al. First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer. N Engl J Med 371, 2167–2177 (2014).
7. Oxnard, G., Binder, A. & Janne, P. New Targetable Oncogenes in Non-Small-Cell Lung Cancer. J Clin Oncol 31, 1097–1104 (2013).
8. Pao, W. New Approaches to Targeted Therapy in Lung Cancer. Proc Am Thorac Soc 9, 72–73 (2012).
9. Li, T., Kung, H., Mack, P. & Gandara, D. Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for 
Current and Future Therapies. J Clin Oncol 31, 1039–1049 (2013).
10. Kris, M. et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA 311, 1998 (2014).
11. Cardarella, S. et al. The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer. J Thorac Oncol 
7, 1767–1774 (2012).
12. Shames, D. & Wistuba, I. The evolving genomic classification of lung cancer. J. Pathol. 232, 121–133 (2014).
13. Roychowdhury, S. et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Sci Transl Med 3, 
111ra121–111ra121 (2011).
14. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev 
Genet 11, 685–696 (2010).
15. Wagle, N. et al. High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively 
Parallel Sequencing. Cancer Discov 2, 82–93 (2012).
16. Mamanova, L. et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 7, 479–479 (2010).
17. Altmüller, J., Budde, B. & Nürnberg, P. Enrichment of target sequences for next-generation sequencing applications in research and 
diagnostics. Biol Chem 395 (2014).
Characteristic N = 58 %
Gender
 Male 28 48.3
 Female 30 51.7
Age
 Average 61.9 –
 Range 38–81 –
Smoker
 Never 33 56.9
 Light (pack-year < 30) 5 8.6
 Heavy (pack-year > 30) 20 34.5
Grade
 G1 13 22.4
 G2 38 65.5
 G3 7 12.1
Stage
 I 21 36.2
 II 13 22.4
 III 17 29.3
 V 7 12.1
Tumour content
 10%–30% 31 53.4
 30%–70% 25 43.1
 > 70% 2 3.4
Table 6.  Demographic and histopathological features of the prospective samples.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:22338 | DOI: 10.1038/srep22338
18. Choi, M. et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci 106, 
19096–19101 (2009).
19. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer 
medicine. EMBO Mol Med 2, 146–158 (2010).
20. Kerick, M. et al. Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) 
tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics 4, 68 (2011).
21. Frampton, G. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA 
sequencing. Nat Biotechnol 31, 1023–1031 (2013).
22. Xuan, J., Yu, Y., Qing, T., Guo, L. & Shi, L. Next-generation sequencing in the clinic: Promises and challenges. Cancer Lett 340, 
284–295 (2013).
23. Pritchard, C. et al. Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, 
Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. J Mol Diagn 16, 56–67 (2014).
24. Wang, J. et al. The diploid genome sequence of an Asian individual. Nature 456, 60–65 (2008).
Acknowledgements
This work was supported by Guangzhou Key Laboratory of Cancer Trans-Omics Research (GZ2012, NO348) and 
Guangzhou science and technology project (201400000001-2).
Author Contributions
J.H., J.W. and J.W. developed the concept. D.S. designed the experiments and wrote the manuscript. L.W., M.Y., 
R.D. and L.L. performed the experiments. J.L., S.C., X.C. and Z.L. developed analytical pipeline software and 
performed the bioinformatics analyses. Y.L., W.L., P.H., L.F. and X.G. provided patient specimens and conducted 
histopathological examinations. All authors discussed the results and conducted commented on the manuscript 
at all stages.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Shao, D. et al. A targeted next-generation sequencing method for identifying clinically 
relevant mutation profiles in lung adenocarcinoma. Sci. Rep. 6, 22338; doi: 10.1038/srep22338 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
